Amgen’s Repatha Data Reinforces Cardiovascular Franchise And Valuation Debate

Amgen’s Repatha data from the VESALIUS-CV Phase 3 subgroup study demonstrates significant reduction in major cardiovascular events for high-risk diabetic patients, reinforcing its cardiovascular franchise. This positions Repatha as the only PCSK9 inhibitor with evidence in both primary and secondary prevention. While the stock has seen long-term growth, investors will monitor how this data influences clinical guidelines, payer decisions, and the long-term demand for Amgen’s cholesterol-lowering drugs, especially considering the company’s debt not being well covered by operating cash flow.